AbCellera and Incyte have entered a strategic partnership for the discovery and development of therapeutic antibodies in oncology.
Incyte will gain the rights to develop and commercialise the therapeutic cancer antibodies that result from the alliance.
AbCellera will receive research payments, downstream clinical and regulatory milestone payments and royalties for net product sales from Incyte.
Incyte BioTherapeutics vice-president Patrick Mayes stated: “This collaboration supports our continued commitment to developing new therapeutics that may improve and expand treatment options for patients with cancer.
“We are excited to partner with AbCellera to initiate this research and look forward to collaborating with them to identify new antibody therapeutics that may address unmet needs in oncology.”
AbCellera focuses on rapidly making available improved medicines by breaking barriers to the standard discovery process of antibody drugs.
Its engine merges specialist teams, technology, and the data science and automation required to expedite antibody-based therapies from target to clinic in a range of therapeutic fields.
AbCellera Partnering senior vice-president Murray McCutcheon stated: “We are excited to partner with Incyte, which has a track record of developing first-in-class medicines and bringing them to patients in need.
“We look forward to working as an extension of Incyte’s team to address complex antibody discovery challenges and accelerate the development of Incyte’s preclinical pipeline of oncology medicines.”
In June 2023, AbCellera entered a research collaboration with Confo Therapeutics for the discovery of specific G protein-coupled receptor ligand (GPCR)-targeting antibody candidates.
